Get started
Author

Frédérique Spyratos

Observed names: F Spyratos, F. Spyratos, FRÉDÉRIQUE SPYRATOS, Frederique Spyratos, Frédérique Spyratos, Fréderique Spyratos, Spyratos, Frédérique
Observed institutions: Inserm, Institut Gustave Roussy, Assistance Publique Hôpitaux de Marseille, Hôpital René Huguenin, Hôpital Saint-Louis, Institut Curie
OpenAlex ID: A5111463210
Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients
2002 · M. P. Look, W. L. J. van Putten, et al. · JNCI Journal of the National Cancer Institute · 596
PDF
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
2011 · Elisabeth Luporsi, Fabrice André, et al. · Breast Cancer Research and Treatment · 333
PDF
Cathepsin D: an Independent Prognostic Factor for Metastasis of Breast Cancer
1989 · Frédérique Spyratos, Kamel Hacene, et al. · The Lancet · 317
Correlation between MIB‐1 and other proliferation markers
2002 · Frédérique Spyratos, Magali Ferrero‐Poüs, et al. · Cancer · 185
Immunocytochemical study with monoclonal antibodies to progesterone receptor in human breast tumors.
1987 · M Perrot-Applanat, M T Groyer-Picard, et al. · PubMed · 118
DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients – Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group
2007 · Sabine Maier, Inko Nimmrich, et al. · European Journal of Cancer · 117
PIK3R1 underexpression is an independent prognostic marker in breast cancer
2013 · Magdalena Cizkova, Sophie Vacher, et al. · BMC Cancer · 115
PDF
DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy
2008 · Oliver Hartmann, Frédérique Spyratos, et al. · Clinical Cancer Research · 103
PDF
Validation of tumor‐associated macrophage ferritin light chain as a prognostic biomarker in node‐negative breast cancer tumors: A multicentric 2004 national PHRC study
2011 · Pascal Jézéquel, Loïc Campion, et al. · International Journal of Cancer · 85
PDF
miRNA expression profiling of inflammatory breast cancer identifies a 5‐miRNA signature predictive of breast tumor aggressiveness
2013 · Florence Lerebours, Geraldine Cizeron‐Clairac, et al. · International Journal of Cancer · 75
Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer
2008 · Sandra E Ghayad, Julie A Vendrell, et al. · Journal of Molecular Endocrinology · 73
PDF
Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy
2011 · Ivan Bièche, Sophie Vacher, et al. · Molecular Cancer · 70
PDF
Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome
2007 · Vincent Vuaroqueaux, Patrick Urban, et al. · Breast Cancer Research · 65
PDF
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases
2013 · Jocelyne Jacquemier, Frédérique Spyratos, et al. · BMC Cancer · 62
PDF
Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. Cytomorphologic changes, initial tumor ploidy, and tumor regression
1989 · Marianne Briffod, Frédérique Spyratos, et al. · Cancer · 62
PDF
Dissemination Risk Index Based on Plasminogen Activator System Components in Primary Breast Cancer
1999 · Cécile Bouchet, Kamel Hacène, et al. · Journal of Clinical Oncology · 61
S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study.
2001 · A Chassevent, M L Jourdan, et al. · PubMed · 59
Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients
2003 · Mamime Look, Wim van Putten, et al. · Thrombosis and Haemostasis · 58
Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. II. DNA flow cytometry changes during chemotherapy, tumor regression, and short-term follow-up
1992 · Frédérique Spyratos, Marianne Briffod, et al. · Cancer · 57
The Parathyroid Hormone–Related Protein (PTHrP) Gene: Use of Downstream TATA Promotor and PTHrP 1–139 Coding Pathways in Primary Breast Cancers Vary with the Occurrence of Bone Metastasis
1999 · Zhor Dr. Bouizar, Frederique Spyratos, et al. · Journal of Bone and Mineral Research · 54
Epidermal growth factor receptors and prognosis in primary breast cancer
1990 · Frédérique Spyratos, Jean-Claude Delarue, et al. · Breast Cancer Research and Treatment · 54
CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients
2010 · Dimo Dietrich, Manuel Krispin, et al. · BMC Cancer · 49
PDF
Prognostic of DNA-synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1-T2, N0-N1, M0 breast cancers: A retrospective multicenter study
2000 · Sylvie Romain, Frédérique Spyratos, et al. · International Journal of Cancer · 38
PDF
Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients
2011 · Patricia de Cremoux, Fabien Valet, et al. · BMC Cancer · 37
PDF
Timing of surgery in breast cancer
1991 · WilliamJ.M. Hrushesky, TrevorJ. Powles, et al. · The Lancet · 36
Works count: 64
Citation count: 3,312
H-index: 30
I10-index: 42
Year
Topic
Type